Publications Archive - Page 34 of 50

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial

Schoenfeld, J. D., Hanna, G. J., Jo, V. Y., Rawal, B., Chen, Y. H., Catalano, P. S., Lako, A., Ciantra, Z., Weirather, J. L., Criscitiello, S., Luoma, A., Chau, N., Lorch, J., Kass, J. I., Annino, D., Goguen, L., Desai, A., Ross, B., Shah, H. J., Jacene, H. A., … Haddad, R. I. (2020). Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA oncology, 6(10), 1563–1570. https://doi.org/10.1001/jamaoncol.2020.2955

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial Read More »

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma

Guest Account

Ng, H., Lee, R. Y., Goh, S., Tay, I., Lim, X., Lee, B., Chew, V., Li, H., Tan, B., Lim, S., Lim, J., Au, B., Loh, J., Saraf, S., Connolly, J. E., Loh, T., Leow, W. Q., Lee, J., Toh, H. C., Malavasi, F., … Lim, T. (2020). Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. Journal for immunotherapy of cancer, 8(2), e000987. https://doi.org/10.1136/jitc-2020-000987

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma Read More »

CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease

Guest Account

Slabik, C., Kalbarczyk, M., Danisch, S., Zeidler, R., Klawonn, F., Volk, V., Krönke, N., Feuerhake, F., Ferreira de Figueiredo, C., Blasczyk, R., Olbrich, H., Theobald, S. J., Schneider, A., Ganser, A., von Kaisenberg, C., Lienenklaus, S., Bleich, A., Hammerschmidt, W., & Stripecke, R. (2020). CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease. Molecular therapy oncolytics, 18, 504–524. https://doi.org/10.1016/j.omto.2020.08.005

CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease Read More »

Complement factor H-deficient mice develop spontaneous hepatic tumors

Guest Account

Laskowski, J., Renner, B., Pickering, M. C., Serkova, N. J., Smith-Jones, P. M., Clambey, E. T., … & Thurman, J. M. (2020). Complement factor H-deficient mice develop spontaneous hepatic tumors. The Journal of Clinical Investigation.

Complement factor H-deficient mice develop spontaneous hepatic tumors Read More »

Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

Guest Account

Topalian, S. L., Bhatia, S., Amin, A., Kudchadkar, R. R., Sharfman, W. H., Lebbé, C., … & Chung, C. H. (2020). Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 Trial. Journal of Clinical Oncology, JCO-20.

Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial Read More »

Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma

Guest Account

Robinson, M. H., Vasquez, J., Kaushal, A., MacDonald, T. J., Vega, J. E. V., Schniederjan, M., & Dhodapkar, K. (2020). Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. Journal for immunotherapy of cancer, 8(2).

Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma Read More »

An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results

Guest Account

Gann, P. H., Deaton, R. J., McMahon, N., Collins, M. H., Dellon, E. S., Hirano, I., … & Harris, S. (2020). An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: phase 2 trial results. Journal of Allergy and Clinical Immunology.

An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results Read More »

Astrocyte layers in the mammalian cerebral cortex revealed by a single-cell in situ transcriptomic map

SIGIRR/TIR8, an important regulator of TLR4 and IL-1R–mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas

Publications

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma

CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease

Complement factor H-deficient mice develop spontaneous hepatic tumors

Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma

An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results

Astrocyte layers in the mammalian cerebral cortex revealed by a single-cell in situ transcriptomic map

SIGIRR/TIR8, an important regulator of TLR4 and IL-1R–mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas

Beta-catenin is elevated in human benign prostatic hyperplasia specimens compared to histologically normal prostate tissue.

Follow Us

More Links

Stay Connected